136 related articles for article (PubMed ID: 38091574)
1. Auto-HCT May Be Best after Chemo in DLBCL.
Cancer Discov; 2023 Dec; ():OF1. PubMed ID: 38091574
[TBL] [Abstract][Full Text] [Related]
2. Autologous transplant vs chimeric antigen receptor T-cell therapy for relapsed DLBCL in partial remission.
Shadman M; Pasquini M; Ahn KW; Chen Y; Turtle CJ; Hematti P; Cohen JB; Khimani F; Ganguly S; Merryman RW; Yared JA; Locke FL; Ahmed N; Munshi PN; Beitinjaneh A; Reagan PM; Herrera AF; Sauter CS; Kharfan-Dabaja MA; Hamadani M
Blood; 2022 Mar; 139(9):1330-1339. PubMed ID: 34570879
[TBL] [Abstract][Full Text] [Related]
3. Postrelapse survival in diffuse large B-cell lymphoma after therapy failure following autologous transplantation.
Epperla N; Badar T; Szabo A; Vaughn J; Borson S; Saini NY; Patel RD; Shah NN; Hamadani M; Ahmed S; Cashen AF; Fenske TS
Blood Adv; 2019 Jun; 3(11):1661-1669. PubMed ID: 31167818
[TBL] [Abstract][Full Text] [Related]
4. ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Diffuse Large B Cell Lymphoma.
Epperla N; Kumar A; Abutalib SA; Awan FT; Chen YB; Gopal AK; Holter-Chakrabarty J; Kekre N; Lee CJ; Lekakis L; Lin Y; Mei M; Nathan S; Nastoupil L; Oluwole O; Phillips AA; Reid E; Rezvani AR; Trotman J; Zurko J; Kharfan-Dabaja MA; Sauter CS; Perales MA; Locke FL; Carpenter PA; Hamadani M
Transplant Cell Ther; 2023 Sep; 29(9):548-555. PubMed ID: 37419325
[TBL] [Abstract][Full Text] [Related]
5. Outcomes of rituximab-BEAM versus BEAM conditioning regimen in patients with diffuse large B cell lymphoma undergoing autologous transplantation.
Jagadeesh D; Majhail NS; He Y; Ahn KW; Litovich C; Ahmed S; Aljurf M; Bacher U; Badawy SM; Bejanyan N; Cairo M; Cerny J; Epperla N; Farhadfar N; Freytes CO; Gale RP; Haverkos B; Hossain N; Inwards D; Kamble RT; Kenkre VP; Lazarus HM; Lazaryan A; Lekakis L; Mei M; Murthy HS; Mussetti A; Nathan S; Nishihori T; Olsson RF; Ramakrishnan Geethakumari P; Savani BN; Yared JA; Fenske TS; Kharfan-Dabaja MA; Sureda A; Hamadani M
Cancer; 2020 May; 126(10):2279-2287. PubMed ID: 32049359
[TBL] [Abstract][Full Text] [Related]
6. Upfront autologous hematopoietic stem cell transplantation consolidation for patients with aggressive B-cell lymphomas in first remission in the rituximab era: A systematic review and meta-analysis.
Epperla N; Hamadani M; Reljic T; Kharfan-Dabaja MA; Savani BN; Kumar A
Cancer; 2019 Dec; 125(24):4417-4425. PubMed ID: 31441943
[TBL] [Abstract][Full Text] [Related]
7. Allogeneic hematopoietic cell transplantation for diffuse large B cell lymphoma: who, when and how?
Klyuchnikov E; Bacher U; Kroll T; Shea TC; Lazarus HM; Bredeson C; Fenske TS
Bone Marrow Transplant; 2014 Jan; 49(1):1-7. PubMed ID: 23708703
[TBL] [Abstract][Full Text] [Related]
8. Impact of Routine Surveillance Imaging on Outcomes of Patients With Diffuse Large B-Cell Lymphoma After Autologous Hematopoietic Cell Transplantation.
Epperla N; Shah N; Hamadani M; Richardson K; Kapke JT; Patel A; Teegavarapu SP; Carrum G; Hari PN; Pingali SR; Karmali R; Fenske TS
Clin Lymphoma Myeloma Leuk; 2016 Dec; 16(12):672-678. PubMed ID: 27660080
[TBL] [Abstract][Full Text] [Related]
9. The role of CAR-T cell therapy as second line in diffuse large B-cell lymphoma.
Albanyan O; Chavez J; Munoz J
Ther Adv Hematol; 2022; 13():20406207221141511. PubMed ID: 36505886
[TBL] [Abstract][Full Text] [Related]
10. Custom CARs: Leveraging the Adaptability of Allogeneic CAR Therapies to Address Current Challenges in Relapsed/Refractory DLBCL.
Jeyakumar N; Smith M
Front Immunol; 2022; 13():887866. PubMed ID: 35663947
[TBL] [Abstract][Full Text] [Related]
11. The Role of Autologous Stem Cell Transplantation in the Treatment of Diffuse Large B-cell Lymphoma in the Era of CAR-T Cell Therapy.
Lekakis LJ; Moskowitz CH
Hemasphere; 2019 Dec; 3(6):e295. PubMed ID: 31976472
[TBL] [Abstract][Full Text] [Related]
12. Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study.
Ansell SM; Minnema MC; Johnson P; Timmerman JM; Armand P; Shipp MA; Rodig SJ; Ligon AH; Roemer MGM; Reddy N; Cohen JB; Assouline S; Poon M; Sharma M; Kato K; Samakoglu S; Sumbul A; Grigg A
J Clin Oncol; 2019 Feb; 37(6):481-489. PubMed ID: 30620669
[TBL] [Abstract][Full Text] [Related]
13. Long-term outcomes among 2-year survivors of autologous hematopoietic cell transplantation for Hodgkin and diffuse large b-cell lymphoma.
Myers RM; Hill BT; Shaw BE; Kim S; Millard HR; Battiwalla M; Majhail NS; Buchbinder D; Lazarus HM; Savani BN; Flowers MED; D'Souza A; Ehrhardt MJ; Langston A; Yared JA; Hayashi RJ; Daly A; Olsson RF; Inamoto Y; Malone AK; DeFilipp Z; Margossian SP; Warwick AB; Jaglowski S; Beitinjaneh A; Fung H; Kasow KA; Marks DI; Reynolds J; Stockerl-Goldstein K; Wirk B; Wood WA; Hamadani M; Satwani P
Cancer; 2018 Feb; 124(4):816-825. PubMed ID: 29125192
[TBL] [Abstract][Full Text] [Related]
14. Autologous and allogeneic hematopoietic cell transplantation for diffuse large B-cell lymphoma-type Richter syndrome.
Herrera AF; Ahn KW; Litovich C; Chen Y; Assal A; Bashir Q; Bayer RL; Coleman M; DeFilipp Z; Farhadfar N; Greenwood M; Hahn T; Horwitz M; Jacobson C; Jaglowski S; Lachance S; Langston A; Mattar B; Maziarz RT; McGuirk J; Mian MAH; Nathan S; Phillips A; Rakszawski K; Sengeloev H; Shenoy S; Stuart R; Sauter CS; Kharfan-Dabaja MA; Hamadani M
Blood Adv; 2021 Sep; 5(18):3528-3539. PubMed ID: 34496026
[TBL] [Abstract][Full Text] [Related]
15. Survival Outcomes for Patients with Relapsed/ Refractory Aggressive B Cell Lymphomas Following Receipt of High-Dose Chemotherapy/Autologous Stem Transplantation and/or Chimeric Antigen Receptor-Modified T Cells.
Landsburg DJ; Nasta SD; Svoboda J; Gerson JN; Schuster SJ; Barta SK; Chong EA; Difilippo H; Weber E; Cunningham K; Catania C; Garfall AL; Stadtmauer EA; Frey NV; Porter DL
Transplant Cell Ther; 2023 Aug; 29(8):495-503. PubMed ID: 37211154
[TBL] [Abstract][Full Text] [Related]
16. Impact of Cell of Origin on Outcomes After Autologous Hematopoietic Cell Transplant in Diffuse Large B-Cell Lymphoma.
Iqbal M; Castano YG; Paludo J; Rosenthal A; Li Z; Beltran M; Moustafa MA; Inwards D; Porrata L; Micallef I; Bisneto JCV; Johnston P; Ansell SM; Reeder C; Murthy H; Roy V; Foran J; Tun HW; Kharfan-Dabaja MA; Ayala E
Clin Lymphoma Myeloma Leuk; 2022 Feb; 22(2):e89-e95. PubMed ID: 34593359
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of chimeric antigen receptor T cell therapy and autologous stem cell transplant in relapsed or refractory diffuse large B-cell lymphoma: A systematic review.
Tian L; Li C; Sun J; Zhai Y; Wang J; Liu S; Jiang Y; Wu W; Xing D; Lv Y; Guo J; Xu H; Sun H; Li Y; Li L; Zhao Z
Front Immunol; 2022; 13():1041177. PubMed ID: 36733398
[TBL] [Abstract][Full Text] [Related]
18. Ofatumumab, Etoposide, and Cytarabine Intensive Mobilization Regimen in Patients with High-risk Relapsed/Refractory Diffuse Large B-Cell Lymphoma Undergoing Autologous Stem Cell Transplantation.
Kambhampati S; Hunter B; Varnavski A; Fakhri B; Kaplan L; Ai WZ; Pampaloni M; Huang CY; Martin T; Damon L; Andreadis CB
Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):246-256.e2. PubMed ID: 33288485
[TBL] [Abstract][Full Text] [Related]
19. Chimeric antigen receptor T-cell therapy combined with autologous stem cell transplantation improved progression-free survival of relapsed or refractory diffuse large B-cell lymphoma patients: A single-center, retrospective, cohort study.
Wang T; Xu L; Gao L; Tang G; Chen L; Chen J; Wang Y; Fu W; Yue W; Ye M; Yu J; Yu X; Feng D; Zhang A; Yang J
Hematol Oncol; 2022 Oct; 40(4):637-644. PubMed ID: 35141937
[TBL] [Abstract][Full Text] [Related]
20. Prognostic differences of refractory/relapsed nodal and extranodal diffuse large B-cell lymphoma in the chimeric antigen receptor T cell therapy era.
Song Z; Xu L; Tang G; Gao L; Wang L; Ni X; Chen L; Chen J; Wang T; Feng D; Yu X; Yang J; Wang Y
Clin Chim Acta; 2022 Jul; 532():72-78. PubMed ID: 35660013
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
